Objective: To explore the molecular mechanism of glucocorticoid (GC)-induced osteoporosis (GIOP).
Methods: Thirty-two female SD rats after matching body weight were divided randomly into three groups: baseline group (n = 10), control group (n = 11) and GC-treated group (n = 11). The administration time was 9 weeks. Bone mineral density (BMD) was measured with dual energy X-ray absorptiometry. A high resolution micro-CT was used to quantify the densitometric and microarchitectural properties of trabeculae in the proximal metaphysis of right tibia. In situ hybridization histochemistry and immunohistochemistry were used to detect the expression of cannabinoid type 1 receptor (CB1R) in the proximal metaphysis of left tibia.
Results: At the end of the experiment, whole-body BMD in vivo in the control group [(0.156 +/- 0.008) g/cm(2)] was higher than that in the baseline group [(0.147 +/- 0.006) g/cm(2)], while the whole-body BMD in vivo [(0.147 +/- 0.006) g/cm(2)] and total BMD in vitro at femurs in the GC-treated group [(0.220 +/- 0.011) g/cm(2)] was lower than those in the control group [(0.240 +/- 0.024) g/cm(2)]. Compared with the baseline group and control group, there was a remarkable decrease in the volumetric BMD, tissue BMD, trabecular number and trabecular connectivity (P < 0.05) in the GC-treated group, while there was a significant increase in trabecular separation (P < 0.05) and trabecular thickness also increased in the proximal metaphysis of tibiae in the GC-treated group. The expression level of CB1R mRNA and protein in osteoclasts in the GC-treated group was markedly higher than that in the baseline group and control group (P < 0.05). There was a close correlation between the expression level of CB1R mRNA, protein in osteoclasts and some microarchitectural parameters in the proximal metaphysis in the GC-treated group (P < 0.05).
Conclusions: The administration of GC is associated with a decrease in BMD and deterioration in microarchitecture of trabecular bone in rats tibiae. Glucocorticoid may up-regulate the CB1R expression level in osteoclasts and this may be a kind of molecular mechanism of GIOP.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.
J Clin Endocrinol Metab
November 2024
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine.
Article Synopsis
- The Wnt/β-catenin signaling pathway is implicated in glucocorticoid-induced osteoporosis (GIOP), and previous studies suggested that inhibiting sclerostin could provide a treatment option.
- The study aimed to evaluate the effectiveness of romosozumab (ROMO), compared to denosumab (DMAb) and bisphosphonates (BP), in increasing bone mineral density (BMD) in patients with rheumatic diseases undergoing glucocorticoid therapy.
- Results showed that ROMO significantly improved lumbar spine BMD after 12 months, indicating that it is a promising treatment for patients with GIOP.
The Lachnospiraceae-butyric acid axis and its role in glucocorticoid-associated osteonecrosis.
J Transl Med
November 2024
Department of Orthopedics, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, Jiangsu Province, 210029, China.
Glucocorticoids (GCs) are key inducers of osteonecrosis, yet not all patients treated with GCs develop glucocorticoid-associated osteonecrosis (GAON). The factors mediating this relationship are unclear. Studies have shown that gut microbiota and their metabolites influence bone metabolism, but their role in GAON is unclear.
View Article and Find Full Text PDFPrognostic Impact of Tumor Growth Rate During Second-line Chemotherapy in Patients With Gastric Cancer.
Cancer Diagn Progn
September 2024
Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Background/aim: Despite the remarkable developments in chemotherapy for gastric cancer (GC), rapid tumor growth is sometimes experienced during chemotherapy. This study investigated the association of tumor growth rate (TGR) during second-line chemotherapy with the prognosis of patients with GC.
Patients And Methods: We retrospectively reviewed 29 patients with GC treated with nab-paclitaxel plus ramucirumab as second-line chemotherapy between 2017 and 2019 at Osaka Metropolitan University.
Glucocorticoid modulates oxidative and thermogenic function of rat brown adipose tissue and human brown adipocytes.
J Cell Physiol
September 2024
Department of Pharmacology, Instituto de Ciencias Biomedicas, Universidade de São Paulo, São Paulo, Brazil.
Chronic and excessive glucocorticoid (GC) exposure can cause Cushing's syndrome, resulting in fat accumulation in selected body areas. Particularly in the brown adipose tissue (BAT), GC acts negatively, resulting in whitening of the tissue. We hypothesized that dysregulation of microRNAs by GC could be an additional mechanism to explain its negative actions in BAT.
View Article and Find Full Text PDFGlucocorticoids disrupt longitudinal advance of cortical bone basic multicellular units in the rabbit distal tibia.
Bone
October 2024
Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada. Electronic address:
Glucocorticoids (GCs) are the leading cause of secondary osteoporosis. The emerging perspective, derived primarily from 2D histological study of trabecular bone, is that GC-induced bone loss arises through the uncoupling of bone formation and resorption at the level of the basic multicellular unit (BMU), which carries out bone remodeling. Here we explore the impact of GCs on cortical bone remodeling in the rabbit model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!